| Literature DB >> 36160072 |
Sahib Rovshanov1, Rahşan Göçmen2, İbrahim Barişta3, Deniz Çağdaş4, Ayşegül Üner5, Vedat Çilingir6, İrsel Tezer Filik1, Çağman Tan4, Elif Soyak Aytekin4, İlhan Tezcan4, Pınar Acar Özen1, Aslı Tuncer1.
Abstract
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) haploinsufficiency is the defect of one of the checkpoint inhibitory molecules and defined as a primary immunodeficiency characterized by immune dysregulation. A 26-year-old female with a history of autoimmune hemolytic anemia, autoimmune thrombocytopenia, and hypogammaglobulinemia was admitted with an inability to walk, urinary hesitancy, and bowel incontinence. Neurological examination revealed mild weakness, pyramidal, and deep sensorial involvement of the left lower extremity. Brain MRI revealed periventricular, juxtacortical, and cerebellar inflammatory lesions. Thoracic spinal MRI showed a longitudinaly extensive cord lesion. Additionally, thoracal CT showed parenchymal opacities and bilateral hilar lymph nodes. The biopsy from mediastinal lymph nodes and lung parenchyma demonstrated a low-grade lymphoproliferation and grade 1 "Lymphomatoid granulomatosis". Detailed laboratory analyses indicated the diagnosis of ''common variable immunodeficiency''. Next-generation sequencing with primary immunodeficiency panel revealed a heterozygous mutation in CTLA-4 (c.436G>A(p.G146R)(p.Gly146Arg)). After molecular diagnosis, abatacept therapy was started as a targeted therapeutic approach with subcutaneous immunoglobulin therapy. Copyright:Entities:
Keywords: CTLA-4 mutation; central nervous system; lymphomatoid granulomatosis
Year: 2022 PMID: 36160072 PMCID: PMC9466633 DOI: 10.29399/npa.27900
Source DB: PubMed Journal: Noro Psikiyatr Ars ISSN: 1300-0667 Impact factor: 1.066